KRAS and colonic neoplasm: Some data suggest the poor efficacy of the available KRAS inhibitors in colon cancer, and Genentech opened two clinical trials of the GDC-6036 compound in combination with one of the following compounds: atezolizumab (NSCLC) or cetuximab, bevacizumab (mCRC), or erlotinib (NSCLC).